Formação médica  

Saiba mais sobre seu médico

 

DANIEL DITZEL SANTOS

 

FORMAÇÃO:

  • FORMADO MÉDICO PELA FACULDADE EVANGELICA DE MEDICINA DO PARANÁ - 1997 
  • MEDICINA INTERNA - HOSPITAL UNIVERSITARIO EVANGÉLICO DE CURITIBA 1999
  • HEMATOLOGIA E HEMOTERAPIA - HOSPITAL UNIVERSITARIO EVANGÉLICO DE CURITIBA 2001
  • SERVIÇO MILITAR EM 2002 CONCLUIU COM HONRA AO MÉRITO PELOS SERVIÇOS PRESTADOS
  • RESEARCH FELLOW - HARVARD UNIVERSITY - 2003 A 2006

ATIVIDADES ATUAIS:

  • MEDICO PREFEITURA MUNICIPAL DE BAURU DESDE 2011
  • MEDICO HOSPITAL SAO LUCAS

PUBLICAÇÕES EM REVISTAS INTERNACIONAIS:

 

2004   Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol., Oct, 15 (10): 1481-3.

 

2004   Treon SP, Tournilhac O, Branagan AR, Hunter Z, Xu L, Hatjiharissi E, Santos DD. Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma, Dec; 5 (3): 205-7.

 

 2005  Hunter ZR, Branagan AR, Manning R, Patterson CJ, Santos DD, Tournilhac O, Dorfman DM, Treon SP. CD5, CD10, and CD23 Expression in Waldenstrom's Macroglobulinemia. Clin Lymphoma, 2005 Mar; 5 (4):246-9. 

 

2005  Tassone P, Neri P, Kutok JL, Tournilhac O, Santos DD, Hatjiharissi E, Munshi V, Venuta S, Anderson KC, Treon SP, Munshi NC. A SCID-hu in vivo model for human Waldenstrom macroglobulinemia. Blood, 2005 May 10.

 

 2005  Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, Richardson P, Munshi NC, Luqman M, Anderson KC. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res, Jul; 65 (13): 5898-906.

 

 2006  Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C, Ditzel Santos D, Hatjiharissi E, Xu L, Leleu X, Tournilhac O, Patterson CJ, Manning R, Branagan AR, Morton CC. Characterization of familial Waldenström’s macroglobulinemia. Ann Oncol, 2006 Mar; 17: 488–494. Epub 2005 December 15.

 

 2006   Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma, 2006 May;  6(6): 478-83.

 

 2006  Tournilhac O, Santos DD, Xu L, Kutok J, Tai YT, Le Gouill S, Catley L, Hunter Z, Branagan AR, Boyce JA, Munshi N, Anderson KC, Treon SP. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol., 2006 Aug; 17 (8): 1275-82. Epub 2006 Jun 20.

 

 2007  leleu X, O'Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP. Hepatitis C viral infection is not associated with Waldenstrom's macroglobulinemia. Am J Hematol. 2007 Jan; 82 (1): 83-4.

 

 2007  Hatjiharissi E, Hansen M, Santos DD, Xu L, Leleu X, Dimmock EW, Ho AW, Hunter ZR, Branagan AR, Patterson CJ, Kortsaris A, Verselis S, Fox E, Treon SP. Genetic linkage of Fc gamma RIIa and Fc gamma RIIIa and implications for their use in predicting clinical responses to CD20-directed monoclonal antibody therapy. Clin Lymphoma Myeloma. 2007 Jan; 7(4):286-90.

 

 2007  Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206.

 

2007  Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007 Oct 1; 110(7):2561-4. Epub 2007 May 2.

 

2007  Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep;35(9):1366-75.

 

2008  Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP. CD27-CD70 interactions in the pathogenesis of Waldenstrom's Macroglobulinemia. Blood. 2008 Dec 1;112(12):4683-9. Epub 2008 Jan 23.

 

 

 2009  Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15;113(3):626-34. Epub 2008 Nov 3.

 

2009  Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr;145(1):59-63. Epub 2009 Feb 6.